Biophytis Identifies False Report Regarding COVA Study
Biophytis reports first-half 2026 results and provides an update on its strategy
Biophytis reports its half-year financial results and provides an update on its strategic outlook.
Biophytis Identifies False Report Regarding COVA Study
Other Press Releases
Read more
Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity
Biophytis today announces the completion of a capital increase through the issue of new shares, accompanied by share subscription warrants, with the removal of the preferential subscription rights of the…
Biophytis to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity
Biophytis today announces that it has submitted to the Brazilian Health Regulatory Agency (ANVISA) an amendment to the protocol of the phase 2 OBA clinical study in obesity.
Biophytis strengthens its financial position and extends its cash runway into Q1 2027
Cash position strengthened to €3.0 million Most 2026 share warrants exercised Phase 2 study in obesity to start in Q1 2027 Hong-Kong JV to start operations for preparing Phase 3…
BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Biophytis today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the Phase 2 OBA clinical trial for obesity in Brazil and shares the…
BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Biophytis provides an update on the rollout of its joint venture in Hong Kong (see details in the “About” section below) and shares its short- and medium-term outlook. Landmark milestones…
